ĐÁNH GIÁ HOẠT ĐỘ ENZYME G6PD TẠI CHỖ BẰNG BỘ CẢM BIẾN ĐỊNH LƯỢNG CARESTARTTM TẠI VÙNG LƯU HÀNH SỐT RÉT PLASMODIUM VIVAX HUYỆN KRÔNG NĂNG, TỈNH ĐẮK LẮK

Abstract

Plasmodium vivax malaria elimination can only be achieved by the deployment of 8‑aminoquinolines (primaquine or tafenoquine) in combination with chloroquine therapy to kill both blood and liver stages. However, this drug group may cause haemolysis in subjects with G6PD deficiency, an X‑linked disorder on red blood cells that is very common in population living in malaria endemic zones. In order to inform the safer use of 8‑aminoquinolines in Krong Nang district, Dak Lak province, a cross-sectional study which included 2,941 subjects was conducted  using a quantitative CareStart™ G6PD biosensor (AccessBio, USA). The results showed that the normal value of G6PD activity is 7.79 IU/g Hb, the 30% and 80% cut-off values were 2.34IU/g Hb and 6.23 IU/g Hb, respectively.The overall prevalence of G6PD deficiency of study population was 4.1%, with the figures for male and female were 4.0% and 4.2%, respectively. The prevalence of G6PD deficiency was significantly different among ethnic groups (p<0.001). The quantitative test should include point-of-care G6PD activity testing in clinical practice, especially in vivax malariato allow the safe use of 8‑aminoquinolines for radical treatment.